Ismail RK, van Breeschoten J, Wouters MWJM, et al. - In the real-world setting, 33% of patients with advanced breast cancer (BC) had palbociclib dose reductions. Dose reductions did not result in poorer overall survival. More dose reductions occurred in older patients, but this had no impact on overall survival.

• Patients (n= 598; median age of 64 years) with advanced BC treated with palbociclib from 2017 to 2020 were included.

• In real-world practice, dose reductions of palbociclib occurred similarly to the PALOMA-3 trial.

• In 23% of the patients, early cessation of palbociclib without dose reductions occurred. Older patients needed a palbociclib dose reduction (median age 67 years vs 63 years).

• A significantly higher time to next treatment (TTNT) and median overall survival (OS) was reported in patients with dose reductions vs those without dose reductions (TTNT= 16.9 vs 11.4 months; median OS= 29.7 vs 21.9 months).

• Older patients (≥70 years) had significantly longer TTNT (16.9 vs 11.6 months) vs younger patients (<70 years), however, a similar OS was noted (20.7 vs 26.7 months).